Santos-Neto Edson Dos, Dantas Daniel Oliveira, Amaral Dillan Cunha, Castro Neto Francisco Carlos de, Louzada Ricardo Noguera, Alves Milton Ruiz
Department of Ophthalmology and Otorhinolaryngology, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil.
Department of Computer Science, Federal University of Sergipe, São Cristóvão, SE, Brazil.
Eye (Lond). 2025 Jul 19. doi: 10.1038/s41433-025-03908-w.
To evaluate the vergence and accommodation parameters of myopic children in the use of 0.025% and 0.05% atropine.
In total, 34 schoolchildren aged between 7 and 17 years were randomly divided into 2 groups: atropine 0.025% (n = 18) and atropine 0.05% (n = 16). The authors evaluated the parameters of accommodation and vergence before (baseline) and after the instillation of 1 drop of medication for 14 nights, on the 15th day in the morning. The accommodative parameters were near point of accommodation (NPA), accommodation amplitude (AA), negative relative accommodation (NRA), positive relative accommodation (PRA), accommodative facility (AF), accommodative lag (AL), and pupillary diameter. The vergence parameters were near point of convergence (NPC), accommodative convergence/accommodation (AC/A) ratio, positive fusional vergence (PFV), and negative fusional vergence (NFV).
There were significant changes in the accommodative parameters: NPA from 5.85 ± 1.75 cm to 11.33 ± 4.58 cm (atropine 0.025%) and from 5.23 ± 1.31 to 14.94 ± 9.36 cm (atropine 0.05%); reduction of AA from 18.58 ± 5.62D to 11.07 ± 6.99D (atropine 0.025%) and from 20.23 ± 5.11 to 9.40 ± 5.32D (atropine 0.05%); reduction of PRA in absolute terms (modulus) from -3.72 ± 1.90 to -2.12 ± 0.79 and from -4.31 ± 1.88 to -2.02 ± 0.98 (atropine 0.05%); reduction of AF from 10.56 ± 3.50 cpm to 5.00 ± 5.59 cpm (atropine 0.025%) and from 11.56 ± 2.16 to 1.94 ± 3.82 cpm (atropine 0.05%); and increase in pupillary diameter from 4.16 ± 0.90 mm to 5.44 ± 0.97 mm (atropine 0.025%) and from 4.04 ± 0.50 mm to 6.69 ± 0.62 mm (atropine 0.05%). In the vergence parameters, only the Near PFV with 0.025% atropine and changes in Far PFV with both 0.025% and 0.05% atropine showed significant differences compared to baseline.
Under the conditions of this study, the use of atropine at concentrations of 0.025% and 0.05% induced significant disturbances in the accommodative system, causing visual discomfort.
评估近视儿童使用0.025%和0.05%阿托品时的聚散和调节参数。
总共34名年龄在7至17岁之间的学童被随机分为2组:0.025%阿托品组(n = 18)和0.05%阿托品组(n = 16)。作者在第14个晚上滴入1滴药物后,于第15天上午评估调节和聚散参数,评估在用药前(基线)和用药后进行。调节参数包括调节近点(NPA)、调节幅度(AA)、负相对调节(NRA)、正相对调节(PRA)、调节灵活度(AF)、调节滞后(AL)和瞳孔直径。聚散参数包括集合近点(NPC)、调节性集合/调节(AC/A)比率、正融像性聚散(PFV)和负融像性聚散(NFV)。
调节参数有显著变化:0.025%阿托品组的调节近点从5.85±1.75厘米变为11.33±4.58厘米,0.05%阿托品组从5.23±1.31厘米变为14.94±9.36厘米;调节幅度0.025%阿托品组从18.58±5.62D降至11.07±6.99D,0.05%阿托品组从20.23±5.11降至9.40±5.32D;正相对调节的绝对值(模量)0.025%阿托品组从-3.72±1.90降至-2.12±0.79,0.05%阿托品组从-4.31±1.88降至-2.02±0.98;调节灵活度0.025%阿托品组从10.56±3.50次/分钟降至5.00±5.59次/分钟,0.05%阿托品组从11.56±2.16降至1.94±3.82次/分钟;瞳孔直径0.025%阿托品组从4.16±0.90毫米增至5.44±0.97毫米,0.05%阿托品组从4.04±0.50毫米增至6.69±0.62毫米。在聚散参数方面,仅0.025%阿托品组的近距正融像性聚散以及0.025%和0.05%阿托品组的远距正融像性聚散与基线相比有显著差异。
在本研究条件下,使用浓度为0.025%和0.05%的阿托品会引起调节系统的显著紊乱,导致视觉不适。